CannPal Animal Therapeutics Limited (CP1) is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The Company is established to research, develop and commercialise regulatory approved, cannabinoid-derived therapeutics, for the global animal health markets, with an initial focus on cats and dogs, in the United States, Europe, Australia and other emerging global markets.
Level 3/43 Bay St, Double Bay NSW 2028, Australia
The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.